Reading Time: 3 minutes A recently published paper, reviewing 15 studies that investigated the effectiveness of riluzole as a treatment for MND in real-time, has suggested that the drug extends survival in people with the disease for much longer than was proposed in the original clinical trials.
Reading Time: 5 minutes This blog is part of the ‘Highlights from Perth’ collection of articles, where you can read about the content of some of the talks and posters presented at the 30th International Symposium on ALS/MND in Perth. With this years International Symposium on ALS/MND now behind us, it is time to reflect on some of the…
Reading Time: 4 minutes This blog is part of the ‘Highlights from Perth’ collection of articles, where you can read about the content of some of the talks and posters presented at the 30th International Symposium on ALS/MND. All presentations have a code beginning with ‘C’ followed by a number (e.g. C50). This will help you locate the specific…
Reading Time: 5 minutes There are literally thousands of websites on the internet that make claims about amazing alternative or off-label treatments (AOTs) and even cures for MND but with little or no scientific evidence to back these claims up. This presents a real problem for people living with the disease who may want to try them. Are they…
Reading Time: 6 minutes ‘From antibiotics and insulin to blood transfusions and treatments for cancer or HIV, virtually every medical achievement in the past century has depended directly or indirectly on research using animals’ – from the Royal Society’s position statement on the use of animals in research. We know that talking about using animals in research is an…
Reading Time: 7 minutes Is it possible that a drug that treats congestive heart failure could improve respiration in people with MND? Or that a drug used to treat cancer could reduce motor neuron inflammation and possibly slow progression of the disease? In this blog we take a look at drug repurposing – using a drug developed to treat…
Reading Time: 4 minutes This blog is part of the ‘Highlights from Glasgow’ collection of articles, where you can read about the content of some of the talks and posters presented at the 29th International Symposium on ALS/MND. Where to start on a subject as wide and varied as technology and MND? Indeed, this problem is not just limited…
Reading Time: 8 minutes Following on from our previous catch-up blog on clinical management talks presented at the Symposium, here is a continuation that looks at talks focusing on treatment therapies and causes of MND. RNA Binding & Transport RNA is the lesser-known ‘cousin’ of DNA – it contains copies of genetic instructions sent out from the nucleus –…
Reading Time: 4 minutes Looking for a treatment for MND is the ultimate goal of the whole MND community. Unfortunately, as MND is a very complicated disease, it is not as easy as it may sound. Setting aside the sheer cost of running trials, researchers have to look at all the possible causes of MND (the genes, lifestyle and…
Reading Time: 5 minutes It’s been over a month since the announcement by the FDA of their decision to licence edaravone / Radicava for people with MND in the USA. The speed of the FDA’s decision took the drug company MT Pharma and the MND research community by suprise. It is encouraging that edaravone has been licenced to treat…
